CARsgen Therapeutics
CARsgen Therapeutics


China · Shanghai, China


Biotechnology · DeepTech · Health


51-200 employees


Series C+

founded in


CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has partnership with Shanghai Cancer Institute and Shanghai Renji Hospital. The company is leading the first tier of CAR-T development, by completing World’s first hepatocellular carcinoma (HCC) and China’s exclusive glioblastoma multiforme (GBM) dose ascending injection tests. Funded by leading venture capital firm BVCF, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide.

Something looks off?
Open jobs at CARsgen Therapeutics
Powered by Getro